Polyrizon
Polyrizon is a biotech company focused on developing and commercializing innovative intranasal products. Their platform technologies include Capture & Contain™ (C&C) and Trap & Target™ (T&T), which aim to protect the human body from airborne threats like allergens, viruses, and molds, and improve drug delivery through the nasal cavity. The company is engaged in research and development of products to prevent and treat respiratory illnesses, allergies, and viral infections, including COVID-19, with a mission to protect patients differently and expand horizons of intranasal care.
Industries
Nr. of Employees
small (1-50)
Products
Trap & Target (T&T)
A drug delivery platform designed for intranasal administration, enhancing the residence time and contact with mucosal tissue to improve the bioavailability of various drugs.
Capture & Contain (C&C)
A polymeric network platform that adheres to the nasal mucosal surface, creating a barrier to capture and contain airborne contaminants like allergens, viruses, and molds.
Trap & Target (T&T)
A drug delivery platform designed for intranasal administration, enhancing the residence time and contact with mucosal tissue to improve the bioavailability of various drugs.
Capture & Contain (C&C)
A polymeric network platform that adheres to the nasal mucosal surface, creating a barrier to capture and contain airborne contaminants like allergens, viruses, and molds.
Expertise Areas
- Intranasal drug delivery
- Mucoadhesive biomaterials and hydrogels
- Controlled-release nasal formulations
- Preclinical antiviral and anti-allergy testing
Key Technologies
- Mucoadhesive polymer networks
- Hydrogel barrier systems
- Biodegradable polymers
- Controlled-release formulation technologies